Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A MULTICENTER, RANDOMIZED, CONTROLLED STUDY TO EVALUATE EFFICACY AND SAFETY OF APREMILAST IN EARLY PSORIATIC ARTHRITIS PATIENTS WITH OLIGOARTHRITIS AND MODERATE DISEASE ACTIVITY: APTITUDE (APremilasT In paTients With oligoarticUlar Psoriatic Arthritis DiseasE

Trial Profile

A MULTICENTER, RANDOMIZED, CONTROLLED STUDY TO EVALUATE EFFICACY AND SAFETY OF APREMILAST IN EARLY PSORIATIC ARTHRITIS PATIENTS WITH OLIGOARTHRITIS AND MODERATE DISEASE ACTIVITY: APTITUDE (APremilasT In paTients With oligoarticUlar Psoriatic Arthritis DiseasE

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 Jan 2019

At a glance

  • Drugs Apremilast (Primary)
  • Indications Psoriatic arthritis
  • Focus Therapeutic Use
  • Acronyms APTITUDE; FOREMOST
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 18 Dec 2018 Planned End Date changed from 31 Mar 2021 to 29 Jan 2021.
    • 18 Dec 2018 Status changed from not yet recruiting to recruiting.
    • 27 Nov 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top